177 TateS
Math assumes U-100 insulin syringes (1 mL = 100 units)
PMID: 37729871 The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
Ready to get started with a tailored weight-loss treatment plan
The evidence was based on experimental data only briefly described in the patent and included models of: gastric ulcers, heart damage, liver damage, pancreatic injury, kidney damage, experimental diabetes, fever, edema, rhinitis, bone fracture, burns, skin wounds, hypersensitivity reactions, pupil dilation, colon injury, tumour growth, radiation injury, red blood cell development, fertility and lactation, tooth damage, several types of central and peripheral nerve damage, and survival from infection with Trichinosis (i.e., tapeworms) as well as several viruses